目标:肌肉力量,功能状态,和肌肉酶通常用于评估特发性炎性肌病(IIM)的疾病状态。本研究旨在探讨定量肌肉超声在评估IIM患者疾病状态中的作用。
方法:IIM患者,不包括包涵体肌炎,与年龄和性别匹配的健康对照(HC)一起招募。所有参与者都接受了肌肉超声和临床评估。使用标准化方案单侧扫描了六个肢体肌肉,测量肌肉厚度(MT)和回声强度(EI)。结果与HC进行了比较,并与结果测量结果相关。
结果:招募了20例IIM患者和24例HC。IIM的亚型为皮肌炎(6),坏死性肌炎(6),多发性肌炎(3),抗合成酶综合征(3),和非特异性肌炎(2)。平均病程为8.7±6.9年。患者和对照组之间的人口统计学和人体测量学没有显着差异。IIM患者股直肌MT明显低于HC。IIM患者肱二头肌和股肌EI高于HC。股直肌MT与改良Rankin量表有中等相关性,医师全球活动评估,和健康评估问卷,以及肱二头肌和手动肌肉测试-8之间的EI。
结论:肌肉超声可以检测IIM患者的近端肌肉萎缩和高回声性。这些发现与临床结果指标相关,使其成为评估疾病晚期IIM患者疾病活动的潜在工具。
OBJECTIVE: Muscle strength, functional status, and muscle enzymes are conventionally used to evaluate disease status in idiopathic inflammatory myopathies (IIM). This study aims to investigate the role of quantitative muscle ultrasound in evaluating disease status in IIM patients.
METHODS: Patients with IIM, excluding inclusion body myositis, were recruited along with age- and sex-matched healthy controls (HC). All participants underwent muscle ultrasound and clinical assessments. Six limb muscles were unilaterally scanned using a standardized protocol, measuring muscle thickness (MT) and echo intensity (EI). Results were compared with HC, and correlations were made with outcome measures.
RESULTS: Twenty IIM patients and 24 HC were recruited. The subtypes of IIM were dermatomyositis (6), necrotizing myositis (6), polymyositis (3), antisynthetase syndrome (3), and nonspecific myositis (2). Mean disease duration was 8.7 ± 6.9 years. There were no significant differences in demographics and anthropometrics between patients and controls. MT of rectus femoris in IIM patients was significantly lower than HC. Muscle EI of biceps brachii and vastus medialis in IIM patients were higher than HC. There were moderate correlations between MT of rectus femoris and modified Rankin Scale, Physician Global Activity Assessment, and Health Assessment Questionnaire, as well as between EI of biceps brachii and Manual Muscle Testing-8.
CONCLUSIONS: Muscle ultrasound can detect proximal muscle atrophy and hyperechogenicity in patients with IIM. The findings correlate with clinical outcome measures, making it a potential tool for evaluating disease activity of patients with IIM in the late phase of the disease.